<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04604990</url>
  </required_header>
  <id_info>
    <org_study_id>E-19-3955/8</org_study_id>
    <nct_id>NCT04604990</nct_id>
  </id_info>
  <brief_title>National Systemic Lupus Erythematosus Prospective Cohort, Saudi Arabia</brief_title>
  <official_title>National Systemic Lupus Erythematosus Prospective Cohort, Saudi Arabia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Saud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Saud University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SLE disease in Saudi Arabia is yet not well defined especially in a population with high&#xD;
      consanguinity and high inbreeding coefficient . Up until now, there has been no prospective&#xD;
      cohort study for SLE patients in Saudi Arabia. As a result, current published literature is&#xD;
      focused on retrospective chart reviews which are subjected to many forms of bias. so the&#xD;
      investigator proposed this prospective registry which will follow open cohort study design&#xD;
      aiming to provide better understanding of disease presentation, course and outcomes&#xD;
      especially if complemented by detailed immunological, molecular, genetic and microbiome data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2050</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2050</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Accrual damage among SLE patients in Saudi Arabia</measure>
    <time_frame>over 10 years</time_frame>
    <description>SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000 (0-150) higher score representing higher disease activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Accrual damage among SLE patients in Saudi Arabia</measure>
    <time_frame>over 10 years</time_frame>
    <description>SLICC/ACR DI, Systemic Lupus International Collaboration Clinics/ American College of Rheumatology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Accrual damage among SLE patients in Saudi Arabia</measure>
    <time_frame>over 10 years</time_frame>
    <description>Mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcome</measure>
    <time_frame>over 5 years</time_frame>
    <description>PROMIS ( Patient Reported Outcome Measurement Information Scale) there are several data collection tool for calculating score (will use REDCap auto score). Each question usually has 5 response option ranging in value from one to five. For example, the adult 8-item, the lowest possible score is 8, the highest possible score is 40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcome</measure>
    <time_frame>over 5 years</time_frame>
    <description>Medication adherence by using Modified Medication Adherence Response Scale (Modified MARS), an overall score of 4 and above is considered adherent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal and maternal outcomes in patients with SLE</measure>
    <time_frame>over 5 years</time_frame>
    <description>Intrauterine fetal death, Abortion, Still birth, Eclampsia and pre-eclampsia, disease Activity</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>SLE (Systemic Lupus)</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Each patient will have two comprehensive visit during which 4 heparin blood tubes will be&#xD;
      collected from the patient for biobanking storage (exception will be for pregnant patients&#xD;
      who will have biological sample collection at the beginning of each trimester along with&#xD;
      postpartum sample (six weeks from delivery).&#xD;
&#xD;
      Once the blood is withdrawn, it will be sorted into:&#xD;
&#xD;
      plasma separation, (immune cell sorting using flow cytometry to into major cell line&#xD;
      including T-cells, B cells, mononuclear cells and granulocytes/versus storage as PBMC - the&#xD;
      decision will be guided by available fund), RNA and DNA then stored at appropriate&#xD;
      temperature using patient unique research identification number.&#xD;
&#xD;
      For DNA processing; blood will be collected using standardized phlebotomy technique directly&#xD;
      into PAXgene Blood DNA tubes.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited from KSU-SLE specialized clinic. The clinic receive general&#xD;
        referral from general rheumatology clinics in KSU and general referral from other clinics&#xD;
        inside or outside KSU. The estimated number is 1000 patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients defined as age greater than 18 years old.&#xD;
&#xD;
          2. Patients should fulfil one of the following classification criteria for SLE (ACR,&#xD;
             SLICC or ACR/EULAR criteria).&#xD;
&#xD;
          3. No restriction on time of diagnosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who don't fulfil classification criteria mentioned above.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Ibrahim Almaghlouth, MSc(c), AmBIM, FRCPC, FACR</last_name>
    <phone>966544282266</phone>
    <email>ialmaghlouth@ksu.edu.sa</email>
  </overall_contact>
  <location>
    <facility>
      <name>king Saud University medical city</name>
      <address>
        <city>Riyadh</city>
        <state>Central Province</state>
        <zip>61961</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ibrahim Almaghlouth</last_name>
      <phone>966118066932</phone>
      <phone_ext>0</phone_ext>
      <email>ialmaghlouth@ksu.edu.sa</email>
    </contact>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 12, 2020</study_first_submitted>
  <study_first_submitted_qc>October 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Saud University</investigator_affiliation>
    <investigator_full_name>Ibrahim Almaghlouth</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>SLE</keyword>
  <keyword>Lupus erythematosus</keyword>
  <keyword>Outcomes</keyword>
  <keyword>Phenotypes</keyword>
  <keyword>Observational</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>upon recruitment, informed consent form will be shared and before enrolment.</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT04604990/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

